All News
ACR 2025 – Day 2 Report
Here are 3 abstracts that caught my eye on Day 2 at ACR25. Notably these have takeaway messages that should support your current practices.
Read Article
Excited (and a little nervous!) to be presenting on a topic I’m very passionate about- social determinants of health & shared decision making, alongside some fantastic speakers & chairs.
Join us in room W184D, 10:00-11:30
Looking forward to a lively discussion!
#ACR25 @RheumNow https://t.co/FsDDrjisR3
Mrinalini Dey DrMiniDey ( View Tweet)
#ClinicalPearl
#seroneg #arthritis often has
👇
#involvement of
1st toe IP joint
Look at the feet 🦶
@RheumNow @ACRheum #ACR25
#28T08
Session secrets &pearls Tues https://t.co/EfqkLsTKmt
Janet Pope Janetbirdope ( View Tweet)
Overview of the use of SARD-ILD by @drdavidliew covering the challenges, professionalism, explainability and interpretability. Think of using and validating AI in the same way we train our residents. The human interface still needed @RheumNow #ACR25 https://t.co/TYKud057ag
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/ZgZM14L6ta
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Day 1 RECAP
Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.
https://t.co/js5FVBvUfk https://t.co/smh1AyPhfa
Dr. John Cush RheumNow ( View Tweet)
Delay in PsA diagnosis
Meta Analysis of 32000+ pts
Median diagnostic delay 2.5 years
Median delay in referral 1 year
Increase odds of Rx damage from 50%
Geographic variation
We need to do better
#ACR25 @RheumNow #ABSTRACT1713 https://t.co/CWwqosa5NT
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
PMR patients need healthcare professionals who know a bit about their disease.
Survey of US HCPs, amongst responders:
- 68% were not aware/unsure about PMR
- of those who were aware, knowledge was… not great (see below)
PMR needs everyone’s respect
#ACR25 ABST1617 @RheumNow https://t.co/SpyEnAW8lI
David Liew drdavidliew ( View Tweet)
In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
At the Global Rheum Summit, patients called for care that values people, not just disease.
✅ Respect lived experience
✅ Enable shared decisions
✅ Support education & coordination of care decisions.
@RheumNow #ACR25
Jiha Lee JihaRheum ( View Tweet)
Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ
Richard Conway RichardPAConway ( View Tweet)
Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT
Richard Conway RichardPAConway ( View Tweet)
Really useful observational study, 305 pts with TAK
Out of 205 pts w/subsequent imaging, 72 (35%) w/NEW lesions in previously-unaffected territory
Majority of lesions stenotic. Emphasizes importance of regular monitoring
#ACR25 @RheumNow Abstr#1631 https://t.co/zoWjH0lEym
Links:
Mike Putman EBRheum ( View Tweet)
After At-risk RA, time to discuss At-risk PsA patients
ARP-PsA
Prospective cohort 1400+ pts
8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology)
Risk factors:
Pso >15 years
Pso + Family Hx
US synovitis/enthesitis
At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
@RheumNow on virtual learning:
It’s integrated in clinical care, research and #MedEd
How to manage info overload?
- schedule, make use of tools
- use AI to curate, analyze & focus
#ACR25 @rheumarhyme https://t.co/ogCezlnxUP
Links:
sheila RHEUMarampa ( View Tweet)
Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use.
ACR's Rheum for Primary Care resource can help address access gap and improve RA care
@RheumNow #ACR25 Abstract#1025
Jiha Lee JihaRheum ( View Tweet)
#1263 More from our health literacy work!
@KingsCollegeNHS, 11 distinct health literacy profiles were identified from 263 rheum patients. Lower literacy linked to unemployment & non-White ethnicity, highlighting equity gaps in care & need for improved resources
@RheumNow #ACR25 https://t.co/QxzMFLykyE
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
